Across TCGA pan-cancer cohorts, MIR182 RNA is linked to patient survival in 18 of 34 cancer types, making it the most broadly survival-associated MIR182 data layer.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher MIR182 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated MIR182 expression acts as an unfavorable survival marker, although some lineages such as TGCT show a favorable association.
UCEC, COAD, and PAAD are the cancer types where MIR182 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.